Cancer despite immunosurveillance: immunoselection and immunosubversion
The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Abstract
Numerous innate and adaptive immune effector cells and molecules participate in the recognition and destruction of cancer cells, a process that is known as cancer immunosurveillance. But cancer cells avoid such immunosurveillance through the outgrowth of poorly immunogenic tumour-cell variants (immunoselection) and through subversion of the immune system (immunosubversion). At the early stages of carcinogenesis, cell-intrinsic barriers to tumour development seem to be associated with stimulation of an active antitumour immune response, whereas overt tumour development seems to correlate with changes in the immunogenic properties of tumour cells. The permanent success of treatments for cancer might depend on using immunogenic chemotherapy to re-establish antitumour immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cancers must escape from immunosurveillance to advance to a clinically detectable state, meaning that they either are passively selected to ''hide'' from immune recognition (immunoselection) or actively suppress immune effectors (immunosubversion).249”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [249]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 1×
“By contrast, it is thought that TGFβ can also have immunostimulatory effects (in particular, on specific T H -cell subset”
BackgroundCuriel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The Pathophysiology of Mitochondrial Cell Death
Green, D. R., & Kroemer, G. (2004) · Science · doi:10.1126/science.1099320 · Cited by 3,418
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“More importantly, tryptophan degradation by indoleamine 2,3-dioxygenase ( IDO ), which is constitutively expressed by human tumours (particularly by prostate, colon and pancreatic carcinomas, but also by interdigitating DCs), promotes resistance to immune-mediated rejection of the tumour cell”
BackgroundImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Cited by
Items 901–1,000 of 1,000
Sandvik, L. F., Skarstein, K., Krynitz, B., Volchenkov, R., Sviland, L., Leivestad, T., Jonsson, R., & Appel, S. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13151 · Cited by 7
Caniceiro, B. D., Latorre, A. O., Fukumasu, H., Sanches, D. S., Haraguchi, M., & Górniak, S. L. (2014) · Journal of Immunotoxicology · doi:10.3109/1547691x.2014.885619 · Cited by 8
“Suppression of NK cell activity has already been related to the escape of tumoral cells and, consequently, cancer growth (Zitvogel et al., 2006).”
BackgroundHistorical Perspectives and Current Trends in Cancer Immunotherapy
Curiel, T. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4732-0_1 · Cited by 8
Lei, K., Li, J., Tu, Z., Liu, F., Ye, M., Wu, M., Zhu, Y., Luo, M., Li, L., Tao, C., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.665870 · Cited by 8
“The TME is highly associated with tumorigenesis, development, and prognosis, and immune cells play critical roles on tumor formation and progression (6, 9, 10).”
BackgroundKalousková, B., Skořepa, O., Cmunt, D., Abreu, C., Krejčová, K., Bláha, J., Sieglová, I., Král, V., Fábry, M., Pola, R., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9111597 · Cited by 8
“Despite all efforts of numerous lymphocyte populations, this process is not always leading to tumor suppression, but may instead result in tumor escape [3,5,6].”
BackgroundJia, J., Cui, J., Liu, X., Han, J.-H., Yang, S., Wei, Y., & Chen, Y. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.01.019 · Cited by 7
Viral gene therapy for head and neck cancer
Hughes, J., Alusi, G., & Wang, Y. (2015) · The Journal of Laryngology & Otology · doi:10.1017/s0022215114003247 · Cited by 7
Goodyear, O. C., Pearce, H., Pratt, G., & Moss, P. A. H. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1070-y · Cited by 7
“There has been considerable interest in the role of the immune response in the control of malignant disease [1].”
BackgroundCancer Immunosurveillance: Immunoediting
Lussier, D. M., & Schreiber, R. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.17001-8 · Cited by 16
Chetty-Sebastian, D., & Assounga, A. G. H. (2023) · BMC Cancer · doi:10.1186/s12885-023-11345-9 · Cited by 7
“Immunosurveillance and immune escape, play a critical role in the prevention and control of cancer [4, 5].”
BackgroundCircular RNAs: key players in tumor immune evasion
Sanati, M., & Ghafouri‐Fard, S. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05186-8 · Cited by 7
“Immunosurveillance denotes the aptitude of the immune system to spot precursors of cancer and abolish these pre-cursors before they become clinically detectable [5, 6].”
DNA and mRNA Vaccines for Chronic Viral Infections and Cancer: Rationale, Mechanisms, and Progress
Liu, M. A. (2022) · Cancers · doi:10.3390/cancers14235874 · Cited by 10
“These include, in addition to the obvious success with which the immune system eliminates a number of acute viral infections, the concept of immunosurveillance (dating back to the early 20th century) a term describing the immune system’s ability to destroy certain tumor cells that arise [1].”
BackgroundRenal Toxicity of Systemic Therapy for Renal Cell Carcinoma
Jaimes, E. A. (2020) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2019.12.006 · Cited by 6
Peixoto, A., Cotton, S., Santos, L. L., & Ferreira, J. A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-73119-9_1 · Cited by 6
Chemotherapy Effects on Immune System
Hota, D., & Tripathy, A. (2022) · Springer eBooks · doi:10.1007/978-981-16-4752-9_13 · Cited by 6
Status and prognostic value of immunological biomarkers of breast cancer
Murazawa, C., Hashimoto, N., Kuraishi, K., Motoyama, M., Hashimoto, S., Ikeuchi, M., Norimura, S., Matsunaga, T., Teramoto, K., Haba, R., et al. (2023) · Oncology Letters · doi:10.3892/ol.2023.13750 · Cited by 9
Halama, N., Zoernig, I., Grabe, N., & Jaeger, D. (2012) · OncoImmunology · doi:10.4161/onci.1.1.18460 · Cited by 6
“chemotherapy induces an immunogenic cell death that leads to renewed activation of the effector immune cells, the recognition of novel epitopes or a general unspecific activation of the immune system and thereby provides new targets to immune cells.(10,26,27) Overall, these findings extend the impact of the local immu…”
BackgroundTan, H., Fiel, M. I., Martin, J. D. R., & Schiano, T. D. (2009) · Liver Transplantation · doi:10.1002/lt.21727 · Cited by 6
“Innate immunologic surveillance and elimination of tumor cells can theoretically be impeded by immunosuppressants via various mechanisms, such as the attenuation of cytotoxic T cell and natural killer cell functions and the disturbance of humoral interactions with macrophages.(5,6) As cytotoxic chemotherapy can produc…”
BackgroundSandvik, L. F., Skarstein, K., Sviland, L., Svarstad, E., Nilsen, A., Leivestad, T., Jonsson, R., & Appel, S. (2014) · Acta Dermato Venereologica · doi:10.2340/00015555-1679 · Cited by 6
Unravelling the complexity of cancer–immune system interplay
Fraser, C. K., Brown, M. P., Diener, K. R., & Hayball, J. D. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.66 · Cited by 8
Polimorfimos en genes de respuesta inflamatoria en cáncer renal metastásico
Sáenz-López, P., Alonso, F. V., Romero, J. M., Carretero, R., Buñuel, M. T., Ruiz‐Cabello, F., & Olmo, J. M. C. (2009) · Actas Urológicas Españolas · doi:10.1016/s0210-4806(09)74180-4 · Cited by 6
TIM-3, a Possible Target for Immunotherapy in Cancer and Chronic Viral Infections.
Tieu, R., Amancha, P. K., Villinger, F. J., & Byrareddy, S. N. (2014) · PubMed · Cited by 7
CD207+/langerin positive dendritic cells in invasive and in situ cutaneous malignant melanoma
Dyduch, G., Tyrak, K. E., Glajcar, A., Szpor, J., & Okoń, K. (2017) · Advances in Dermatology and Allergology · doi:10.5114/ada.2017.67845 · Cited by 7
“However, depending on the biological context, DCs can either boost an effective host reaction to cancer cells or maintain local tissue tolerance that facilitates tumour growth [26, 27].”
BackgroundMaestroni, U. V., Cavalieri, D. M., Campobasso, D., Guarino, G. G., & Ziglioli, F. (2022) · PubMed Central · doi:10.23750/abm.v92i6.12058 · Cited by 6
Identifying tumor antigens in endocrine malignancies
Wuttke, M., Papewalis, C., Jacobs, B., & Schott, M. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2008.12.003 · Cited by 6
Cancer Immunotherapy: Will Expanding Knowledge Lead to Success in Pediatric Oncology?
Fry, T. J., & Lankester, A. C. (2008) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2007.10.015 · Cited by 6
Association of immune evasion in myeloid sarcomas with disease manifestation and patients’ survival
Bauer, M., Monecke, A., Hackl, H., Wilfer, A., Jaekel, N., Bläker, H., Al‐Ali, H. K., Seliger, B., & Wickenhauser, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1396187 · Cited by 5
Hart, S. F. M., Garrett, F. E. S., Kerr, J. S., & Metzger, M. J. (2025) · PLoS Genetics · doi:10.1371/journal.pgen.1011629 · Cited by 6
The Immunoendocrine Network in Breast Cancer
Castro, K. E. N., Arreola, M. I. P., Ostoa‐Saloma, P., Muñiz‐Hernández, S., Cerbón, M. A., Gómez-Icazbalceta, G., Muñoz-Cruz, S., Aguilar-Díaz, H., Pavón, L., Romero, J. I. C., et al. (2014) · Advances in Neuroimmune Biology · doi:10.3233/nib-140097 · Cited by 5
“CD8+ cytotoxic T cells (CTLs) and NK cells are most likely effectors of successful antitumor immunity [85].”
BackgroundCellular Interactions in Nasopharyngeal Carcinomas
Gourzonès, C., Klibi, J., Friboulet, L., JLIDI, R., & Busson, P. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5947-7_6 · Cited by 5
Biological implications of the immune factors in the tumour microenvironment of oral cancer
Shetty, S. S., Padam, K. S. R., Hunter, K. D., Kudva, A., & Radhakrishnan, R. A. (2021) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2021.105294 · Cited by 6
Fasting and cancer: from yeast to mammals
Tano, M. D., & Longo, V. D. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.02.005 · Cited by 7
NKG2D‐mediated cytotoxicity improves after primary surgery for high‐grade serous ovarian cancer
Israelsson, P., Björk, E., Nagaev, I., Nagaeva, O., Lundin, E., Mincheva‐Nilsson, L., & Ottander, U. (2022) · American Journal of Reproductive Immunology · doi:10.1111/aji.13647 · Cited by 5
Wang, S., Song, Y., Shi, Q. W., Qiao, G., Zhao, Y., Zhou, L., Zhao, J., Jiang, N., & Huang, H. (2023) · PubMed Central · Cited by 7
Wu, C., Chang, C.-Y., Chou, P.-Y., Chan, X., Huang, C.-C., Yang, Y., & Liu, H. (2024) · Veterinary Quarterly · doi:10.1080/01652176.2024.2435978 · Cited by 5
“This outcome may result from late-stage cancer cells evading immunosur-veillance through the generation of poorly immunogenic cells and subversion of the immune system (Zitvogel et al. 2006; Dubuisson et al. 2021).”
van Luijn, M. M., van den Ancker, W., van Ham, S. M., & van de Loosdrecht, A. A. (2014) · OncoImmunology · doi:10.4161/21624011.2014.941737 · Cited by 5
Anees, M., Horak, P., Schiefer, A., Vaňhara, P., El‐Gazzar, A., Perco, P., Kiesewetter, B., Müllauer, L., Streubel, B., Raderer, M., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.953149 · Cited by 7
Dong, R., Long, J., Xu, X., Zhang, C., Wen, Z., Li, L., Yao, W., & Zeng, Z. (2014) · BioMedical Engineering OnLine · doi:10.1186/1475-925x-13-2 · Cited by 5
“Presently, it is well confirmed that DCs are dysfunctional in cancer-bearing hosts [10-13].”
BackgroundCancer Immunotherapy: Will Expanding Knowledge Lead to Success in Pediatric Oncology?
Fry, T. J., & Lankester, A. C. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.11.010 · Cited by 6
“Immune pressure may have resulted in the generation of immune escape variants via the mechanism of immuno-editing.(33,34) General mechanisms of immune escape include interference with”
BackgroundT-cell Exhaustion and Cancer Immunotherapy.
Patil, S., Rao, R. S., & Majumdar, B. (2015) · PubMed Central · Cited by 8
MHC-I genotype drives early immune selection of oncogenic mutations
Marty, R., de Prisco, N., Carter, H. K., & Font-Burgada, J. (2017) · Molecular & Cellular Oncology · doi:10.1080/23723556.2017.1409863 · Cited by 5
“The concept of immunosurveillance dictates that tumor cells at early stages of tumor development should also be susceptible to elimination by the immune system.(4) If the initiating cells successfully avoid elimination, they continue to evolve in an environment of selective pressure imposed by the immune sys-”
BackgroundVrdoljak, E., Magri, C., Gamulin, M., Bošković, L., Omrčen, T., Bajić, Ž., Dienes, T., & Géczi, L. (2020) · Neoplasma · doi:10.4149/neo_2020_200512n519 · Cited by 6
Using the COPRAS Methodology Cancer with a solution
(2024) · Computer Science Engineering and Technology · doi:10.46632/cset/1/1/5 · Cited by 5
Gene regulation in glioblastoma: a combinatorial analysis of microRNAs and transcription factors
Gong, X., Sun, J., & Zhao, Z. (2011) · International Journal of Computational Biology and Drug Design · doi:10.1504/ijcbdd.2011.041006 · Cited by 5
“…of cancer’, including self-sufficiency in growth signals, insensitivity to antigrowth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis, tissue invasion and metastasis (Hanahan and Weinberg, 2000) and avoidance of immunosurveillance (Zitvogel et al., 2006).”
BackgroundMethodInfluentialMolecular Oncology in Gynecologic Cancer
Thaker, P. H., & Sood, A. K. (2012) · Elsevier eBooks · doi:10.1016/b978-0-323-06986-1.00026-3 · Cited by 5
Identification of Biomarkers Associated with Cancer Using Integrated Bioinformatic Analysis
Parihar, A., Malviya, S., & Khan, R. (2021) · Biomedical engineering · doi:10.5772/intechopen.101432 · Cited by 5
Augert, A., & Bernar, D. (2013) · InTech eBooks · doi:10.5772/55519 · Cited by 9
“Immunosurveil‐ lance is a term used to define how immune cells identify and destroy abnormal antigen upon recognition [117].”
BackgroundCancer immunology and colorectal cancer recurrence
Vannucci, L. E. (2011) · Frontiers in Bioscience-Scholar · doi:10.2741/233 · Cited by 5
Mueller, K. T., Saavedra, A. A., O’Keeffe, L. A., & Sparks, J. A. (2025) · Drugs & Aging · doi:10.1007/s40266-024-01175-0 · Cited by 7
Luo, L., Wang, B., Li, Q., Zhang, L., Li, C., Jin, A., Qi, H., & Tang, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113869 · Cited by 4
Tehran, M. H., Arab, F. L., Zeynali, F., Mahmoudi, M., Tabasi, N. S., & Khayatzadeh, J. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106406 · Cited by 5
Pancreatic carcinoma development: new etiological and pathogenetic evidence
Fiorino, S., Reggiani, M. L. B., Pontoriero, L., Gallo, C. G., Chili, E., Masetti, M., Zanini, N., Grondona, A., Silvestri, T., Deleonardi, G., et al. (2013) · Italian Journal of Medicine · doi:10.4081/itjm.2013.242 · Cited by 4
Effect of Chemotherapy on the Tumor Microenvironment and Anti-tumor Immunity
Meniawy, T. M., Nowak, A. K., & Lake, R. (2012) · Springer eBooks · doi:10.1007/978-94-007-4694-7_1 · Cited by 4
Nivolumab in renal cell carcinoma
Ortega, R. M. M., & Drabkin, H. A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1049596 · Cited by 4
“and systemic dysfunction in T-cell signaling [28].”
Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer
Kimbro, K. S., & Parker, S. (2009) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489209789206904 · Cited by 4
“In particular, the development of full-blown neoplasia requires that cancer cells have to overcome their autonomous immune pathways as well as those extrinsic immune barriers [89].”
BackgroundGiannios, J. (2015) · InTech eBooks · doi:10.5772/61772 · Cited by 4
Xie, Y., Yan, J., Ma, J., Li, H., Ye, Y., Zhang, Y., & Zhang, H. (2017) · Toxicology Research · doi:10.1039/c7tx00194k · Cited by 4
Analysis of platelet RNA: a non-invasive method for studying the expression of tumor genes
Tesakov, I. P., Martyanov, A. A., Друй, А. Е., & Sveshnikova, A. N. (2021) · Pediatric Hematology/Oncology and Immunopathology · doi:10.24287/1726-1708-2021-20-1-207-217 · Cited by 4
“Известно, что на поверхности многих опухолевых клеток снижена экспрессия главного комплекса гистосовместимости (MHC) I класса [79], что позволяет им избежать уничтожения цитотоксичными Т-лимфоцитами [78].”
Extremity risk factors of sepsis for gastrointestinal endoscopy in patients with liver cirrhosis
Chan, Y.-C., Chen, C., Wang, C.-C., Lin, C.-C., Yong, C., Chiu, K., & Wu, K.-L. (2021) · BMC Gastroenterology · doi:10.1186/s12876-022-02124-0 · Cited by 4
“At present, the mechanism of cancer recurrence is still unknown, but it may result from immunosuppressive therapy, including attenuation of the functions of cytotoxic T-cells and natural killer cells, as well as the disturbance of humoral interaction with macrophages [6].”
BackgroundImmunosenescence, Oxidative Stress, and Cancers
Fülöp, T., Pawelec, G., Dupuis, G., Kotb, R. R., Friguet, B., Witkowski, J. M., & Larbi, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-30845-2_23 · Cited by 4
Mandal, U. K., & Kumar, M. (2022) · Drug Delivery Letters · doi:10.2174/2210303112666220422102459 · Cited by 4
Role of Platelet Activation in the Development and Metastasis of Solid Tumors
Sveshnikova, A. N., Tesakov, I. P., Kuznetsova, S. A., & Shamova, Е. М. (2024) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093024010150 · Cited by 4
“In addition, it is well known that the expression of major histocompatibility complex (MHC) class I is reduced on the surface of many tumor cells [126], allowing them to avoid destruction by cytotoxic T lymphocytes [123].”
Kuhlmann, J. D., Bachmann, H. S., Link, T., Wimberger, P., Kroeber, E. S., Thomssen, C., Mallé, B., Bethmann, D., Vetter, M., & Kantelhardt, E. J. (2019) · Scientific Reports · doi:10.1038/s41598-019-47601-x · Cited by 4
Kuriakose, M. A., Chakrabarti, S., Cheong, S. C., Kowalski, L. P., PINHEIRO, T. N., & Farah, C. S. (2018) · Springer eBooks · doi:10.1007/978-3-319-28100-1_20-1 · Cited by 4
Shakiba, Y., Naberezhnaya, E. R., Кочетков, Д. В., Yusubalieva, G. M., Vorobyev, P. O., Chumakov, P. M., Baklaushev, V. P., & Lipatova, A. V. (2023) · Bulletin of Russian State Medical University · doi:10.24075/brsmu.2023.010 · Cited by 4
Richardson, J. P., & Macmillan, D. (2008) · Springer eBooks · doi:10.1007/978-3-540-30429-6_68 · Cited by 5
Kosoff, D., Krueger, T. E. G., & Lang, J. M. (2013) · Immunotherapy · doi:10.2217/imt.13.116 · Cited by 4
Targeting Foxp1 for Reinstating Anticancer Immunosurveillance
Zitvogel, L., & Kroemer, G. (2014) · Immunity · doi:10.1016/j.immuni.2014.09.001 · Cited by 4
“This is a particularly relevant query as uncontrolled oncogenic processes invariably offer an orchestrated microenvironment where anergy, exhaustion, and senescence account for T cell dysfunctions and tumor escape (Zitvogel et al., 2006, Pardoll, 2012).”
BackgroundNovel Antibody-Based Proteins for Cancer Immunotherapy
Fuenmayor, J., & Montaño, R. F. (2011) · Cancers · doi:10.3390/cancers3033370 · Cited by 5
“Still, activation of an immune response should be a major component of antineoplastic therapies, due to the important role that immunity has on cancer development [104].”
BackgroundVirus‐based immunotherapy of cancer: what do we know and where are we going?
Sørensen, M. R., & Thomsen, A. R. (2007) · Apmis · doi:10.1111/j.1600-0643.2007.00802.x · Cited by 5
“These sMICA compete with membrane-bound MICA, which is a death receptor recognised and induced by NK cells causing NKG2D-mediated killing (19).”
BackgroundInfluentialReasoning the Effect of Immunotherapy After Chemoradiation in the PACIFIC Trial
Bulbul, A., & Araujo-Mino, E. P. (2018) · Future Oncology · doi:10.2217/fon-2018-0464 · Cited by 4
Herbal Medicines as Adjuncts to Cancer Chemotherapy—Part 1: Immunomodulators
Yarnell, E. L., & Zimmerman, C. (2019) · Alternative and Complementary Therapies · doi:10.1089/act.2018.29201.eya · Cited by 4
Biocompatible Glasses Applied in Cancer Treatment: Magnetic Hyperthermia and Brachytherapy
Borges, R., de Souza, A. C. S., Genova, L. A., Machado, J., Justo, G. Z., & Marchi, J. (2022) · Wiley eBooks · doi:10.1002/9781119724193.ch22 · Cited by 5
Catani, G., O’Connor, J. M., Spinelli, A., & Perea, J. (2026) · International Journal of Colorectal Disease · doi:10.1007/s00384-026-05145-3 · Cited by 3
“The increased genomic instability, together with impaired immune surveillance, may contribute to explain the aggressive clinical behavior and advanced stage at diagnosis frequently observed in EOCRC [27–30].”
Re-balancing immunity with CRISPR-Cas9: Novel strategies for cancer and autoimmune disorders
Ren, X., Zhou, Z., Kong, L., Guo, Y., Liu, Y., Li, J., Gu, X., Jiang, C., & Wu, J. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108921 · Cited by 3
Cell Therapy Strategies are also Promising to the Future of Immunotherapy
Tolomelli, G. (2014) · Journal of Hematology & Thromboembolic Diseases · doi:10.4172/2329-8790.1000138 · Cited by 3
“However, within the immune system of cancer patients, the efficacy of vaccin-induced, tumorspecific T cells is significantly hampered by the presence of tumor induced-suppression and regulatory tolerogenic factors [6].”
BackgroundAragón-Franco, R., Ruiz‐Manzano, R. A., Castro, K. E. N., Río‐Araiza, V. H. D., Garay-Canales, C. A., Pérez‐Torres, A., Chacón‐Salinas, R., Girón‐Pérez, M. I., & Morales‐Montor, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1332933 · Cited by 4
“…dynamic tumor microenvironment; when the balance between the interactions of stromal cells, immune cells, and tumors, along with their secretion products, is lost, local “ immunosuppression ” occurs, and non-neoplastic cells acquire a “ pro-tumor ” phenotype which leads to tumor development (5, 6).”
BackgroundLuan, J., Liu, Y., Cao, M., Guo, X., & Guo, N. (2024) · Oncology Reports · doi:10.3892/or.2024.8757 · Cited by 5
“Furthermore, these checkpoints induce T‑cell fatigue in the TME and enhance the immune evasion of cancer cells (13).”
BackgroundOncogenic processes: a neglected parameter in the evolutionary ecology of animals
Thomas, F., Asselin, K., MacDonald, N., Brazier, L., Meliani, J., Újvári, B., & Dujon, A. M. (2024) · Comptes Rendus Biologies · doi:10.5802/crbiol.159 · Cited by 3
Quadri, M., Iuliano, M., Rosa, P., Mangino, G., & Palazzo, E. (2025) · Life · doi:10.3390/life15081170 · Cited by 4
“This response, in turn, selects tumor cell variants that are prone to manipulate the TME, creating the conditions for the shift from M1 to M2 macrophages, which most of the studies on SCC reported as the main TAM subset [77].”
Edholm, E., & Robert, J. (2013) · Resources · doi:10.3390/resources2030167 · Cited by 3
Anti-inflammatory and Antitumor Properties of Eriobotrya Japonica Lindl: Mini-Review
Gómez, X. S. R., Monroy‐Torres, R., & Linares-Segovia, B. (2014) · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · doi:10.2174/187152221401140812144744 · Cited by 3
“Unfortunately, cancer cells are capable of avoiding this process by immunoselection of poorly immunogenic tumor cells along with a subversion of the immune system, thus shaping both the tumor and its microenvironment [47].”
BackgroundCAR-NK cell immunotherapy: Development and challenges toward an off-the-shelf product
Mansour, A. G., Teng, K., Lu, T., Barr, T., & Yu, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00011-4 · Cited by 4
Immunomodulatory properties of nanostructured systems for cancer therapy
Comparetti, E. J., Ferreira, N. N., Ferreira, L. M. B., Kaneno, R., & Zucolotto, V. (2022) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37359 · Cited by 5
Ruiz‐Manzano, R. A., Castro, K. E. N., Arreola, M. I. P., Hernández‐Cervantes, R., Río‐Araiza, V. H. D., Mendoza, M. S., Pérez‐Torres, A., Girón‐Pérez, M. I., & Morales‐Montor, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911944 · Cited by 3
“NK cells are known as cytotoxic cells of the innate response and in tumors, are principal effectors of the cancer immunoediting by recognizing and destroying tumor cells directly through the exocytosis of granules with perforin and granzyme, apoptosis mediated by different death receptors (FasL, TRAIL, and TNF-α), and…”
BackgroundJiang, G., Miao, Y., Wang, Z., Zhang, Q., Zhou, P., & Zhang, F. (2023) · Aging · doi:10.18632/aging.204535 · Cited by 4
Ash, S., & Askenasy, N. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103956 · Cited by 3
Dalens, L., Lecuelle, J., Favier, L., Fraisse, C., Lagrange, A., Kaderbhaï, C., Boidot, R., Chevrier, S., Mananet, H., Dérangère, V., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087592 · Cited by 4
“However, tumor cells have the ability to develop mechanisms of immune evasion, which favors the development of clinically detectable cancers [2].”
BackgroundJAK1 Is a Novel Target of Tumor- and Invasion-Suppressive microRNA 494-5p in Colorectal Cancer
Patil, N., Abdelrahim, O., Leupold, J. H., & Allgayer, H. (2023) · Cancers · doi:10.3390/cancers16010024 · Cited by 4
“Finally, an overexpression of this miR leads to a reduced JAK1, STAT6, and AKT phosphorylation and IL-4-induced migration and invasion; this, together with data from the literature, leads to the conclusion that miR-494-5p is an early tumor and initial metastasis suppressor in CRC.”
ResultExercise and tumor proteome: insights from a neuroblastoma model
Plaza‐Florido, A., Gálvez, B. G., López, J. A., Santos‐Lozano, A., Zazo, S., Rincón‐Castanedo, C., Martín-Ruiz, A., Lumbreras, J., Terron-Camero, L. C., López‐Soto, A., et al. (2024) · Physiological Genomics · doi:10.1152/physiolgenomics.00064.2024 · Cited by 4
Recent Advances in Nanocarrier-mediated Combination Drug Therapy for Tackling Solid-resistant Tumors
Rafiya, K., Awasthi, S., Qureshi, S. A., Hasan, N., & Ahmad, F. J. (2025) · Current Drug Delivery · doi:10.2174/0115672018341670241124150932 · Cited by 5
Foremost Concepts in Mechanisms of De Novo Post-Liver Transplantation Malignancy
Peruhova, M., Peshevska-Sekulovska, M., Panayotova, G. G., & Velikova, T. V. (2021) · Gastroenterology Insights · doi:10.3390/gastroent12030025 · Cited by 4
Tumor Infiltrating Lymphocytes in Breast Cancer: Implementation of a New Histopathological Biomarker
Floris, G., Broeckx, G., Antoranz, A., Schepper, M. D., Salgado, R., Desmedt, C., Peeters, D. J. E., & den Eynden, G. G. G. M. V. (2022) · Springer eBooks · doi:10.1007/978-3-030-98950-7_13 · Cited by 4
The Role of Innate Immune Signaling in Regulation of Tumor-Associated Myeloid Cells
Shime, H., Matsumoto, M., & Seya, T. (2015) · Springer eBooks · doi:10.1007/978-4-431-55327-4_3 · Cited by 3
Current Perspectives on Immunomodulation of NK Cells in Melanoma
Lakshmikanth, T., & Maria, H. (2011) · InTech eBooks · doi:10.5772/23903 · Cited by 4
“microenvironment may result in functional subversion of tumor infiltrating immunocompetent cells (Zitvogel et al., 2006).”
BackgroundA co-stimulatory trap set by myeloid leukemia cells
Esendağlı, G. (2013) · OncoImmunology · doi:10.4161/onci.24524 · Cited by 3
“In other words, tumor cells that can successfully evade antitumor immunity may emerge as a consequence of adaptation to the selective pressure imposed by the immune system.(1) Our results demonstrate the capacity of the leukemia cells to rapidly adapt to antitumor immune responses.”
InfluentialThe cancer critical care paradox
Kelly, P. (2008) · Current Anaesthesia and Critical Care · doi:10.1016/j.cacc.2008.01.002 · Cited by 3
Kaarvatn, M. H., Eftedal, R. K., Vrbanec, J., Jotanović, Z., Etokebe, G. E., Balen, S., Kulić, A., & Dembić, Z. (2012) · Hrčak Portal of scientific journals of Croatia (University Computing Centre) · Cited by 3
Vaccine Immunotherapy Strategies in Colorectal Cancer Treatment
Niccolai, E., & Amedei, A. (2012) · Single Cell Biology · doi:10.4172/2168-9431.1000102 · Cited by 3
“For this purpose, it’s very important that the collaboration between cells of the innate immune system and cells of the adaptive immune system (B and T cells) [7].”
BackgroundImmunostimulatory Effects of Extract from Nori (Porphyra yezoensis) in Vitro and in Vivo
Kitajima, H., Komizu, Y., Ichihara, H., Goto, K., Doi, T., Inano, T., & Ueoka, R. (2013) · KAGAKU KOGAKU RONBUNSHU · doi:10.1252/kakoronbunshu.39.359 · Cited by 3
Metadata
- Authors
- Zitvogel, L., Tesniere, A., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Kroemer, Guido
- Venue
- Nature reviews. Immunology
- Published
- 2006-09-15
- Volume
- 6
- Issue
- 10
- Pages
- 715-727
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2063192133
- Cited by
- 1,324
- References
- 127
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 62 · 2023: 75 · 2022: 68 · 2021: 63 · 2020: 63 · 2019: 60 · 2018: 66 · 2017: 76 · 2016: 72 · 2015: 81 · 2014: 87 · 2013: 89 · 2012: 82
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission
- Conseil Régional, Île-de-France
- Institut National Du Cancer
- Cancéropôle Ile de France
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor surveillance, immunoselection, tumor immunogenicity, antitumor immunity, carcinogenesis, immunogenic chemotherapy
- MeSH terms
- Animals, Humans, Immune Tolerance, Immunologic Surveillance, Neoplasms, T-Lymphocytes, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.